Letter by Rezaei and Arjmand Regarding Article, “Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial” | Zendy

Yousef Rezaei | Zendy; Nasim Arjmand | Zendy

Open Access

Letter by Rezaei and Arjmand Regarding Article, “Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial”

Author(s) -

Yousef Rezaei,

Nasim Arjmand

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.012979

Subject(s) - cerebrolysin , medicine , placebo , stroke (engine) , randomized controlled trial , neuroprotection , alternative medicine , pathology , mechanical engineering , engineering

We read with great interest and appreciation the article by Muresanu et al1 on the effects of cerebrolysin on the improvement of motor function in patients with acute ischemic stroke. Within the word count limitations of this letter, however, we would like to present a point that needs to be addressed and evaluated more in future experimental and clinical studies regarding the cerebrolysin mechanisms of action to improve ischemic stroke outcomes.Cerebrolysin is a neuroprotective medication, which is a porcine brain–derived peptide that acts as a neurotrophic agent similar to growth and neurotrophic …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research